Michael brings more than 20 years of experience in clinical research, drug and medical device development across a wide range of therapeutic areas. He is the CEO of LyGenesis, an organ regenerative startup company that spun out of the McGowan Institute for Regenerative Medicine.
Michael’s drug development experience includes serving as Cypress Bioscience’s Vice President of Corporate and Clinical Development, where he had responsibility for development of the drug and medical device portfolio for multiple CNS assets, including the FDA approval of Savella (milnacipran) for fibromyalgia. Before joining Cypress, he worked at Amylin Pharmaceuticals, leading drug development teams focused on orphan drug development for rare metabolic diseases, and combination peptide and protein therapies for obesity. Michael also served as Vice President of Scientific Affairs at invivodata, where he was responsible for scientific consulting on patient-reported outcome claim construction for more than 50 drug development programs. An entrepreneur, Michael has co-founded and raised venture and angel capital for multiple pharmaceutical, device, and mobile health companies including NQ Oncology, e-Nicotine Technology, and MindApps.
Michael is a graduate of Purdue University. He earned his master’s and doctoral degrees in Clinical Psychology from the University of Pittsburgh before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School.